Livmoniplimab specifically inhibits TGF-ß1 in a GARP-dependent context, which may increase the therapeutic index and/or the tumor-selectivity of this antibody compared with agents that target all TGF-ß isoforms or broadly target TGF-ß1. The gene discussed is LRRC32; the disease is neoplasm.